Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(18):1327; doi:10.1093/jnci/dji327
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Smith, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Oh, Canada: Public Outcry Pushed Demand for Trastuzumab for Early-Stage Breast Cancer

Michael Smith

The first 10% of the full text of this article appears below.

When positive results from three randomized trials of trastuzumab (Herceptin) in locally invasive breast cancer were released earlier this year, patients with early-stage, HER-2–positive breast cancer in Canada were told they would have to wait: Their doctors couldn't prescribe the drug to them, their hospitals couldn't administer it, and their governments wouldn't pay for it.

"Everyone got caught by surprise on this one," said medical oncologist Brent Schacter, M.D., of Cancer Care Manitoba and chief executive officer of the Canadian Association of Provincial Cancer Agencies.


Figure Removed (Available Only in the Full Text)
View larger version (97K):
[in this window]
[in a new window]
  		. . . [Full Text of this Article]

 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?